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INTRODUCTION
B-lymphocytes develop from hematopoietic stem cells through an orderly process of differentiation.
These events underlie the differentiation from a committed B-cell progenitor to precursor and mature B-cells that upon stimulation by antigens undergo terminal differentiation into antibody-secreting plasma and memory B-cells. The early phase of B lymphopoiesis is characterized by the sequential rearrangement of immunoglobulin (Ig) heavy chain (H) and light chain (L) genes. 1 After rearrangement, Ig variable genes can be diversified by HMS, while the effectors functions of the constant domain can be modified by CSR. The occurrence of these processes depends on activation-induced cytidine deaminase (AID), expressed in B-cells from secondary lymphoid organs upon CD40 ligand (CD40L) stimulation. 2 Since the absence of AID expression in one form of hyper-IgM syndrome in humans 3 and in AID targeted mice 4 , abolishes both CSR and SHM, this protein is presumed to play a major role in both processes. 5 In addition to AID, a large panel of genes encoding key proteins involved in B-cell development has been characterized in the past years. 6 The regulation of these genes depends on a complex interplay involving different transcription factors, some of which are ubiquitous whereas the others are essentially expressed in B-cell lineages. Despite great progress in this field, the molecular mechanism of CSR and the protein factors involved in the process are still largely unknown. Different transcription factors as NF-kB/Rel family dividing, monoclonal CD5 + B lymphocytes, which can express Ig V genes displaying either a mutated or unmutated profile. 16 The mutational status of Ig genes has been shown to be associated to disease prognosis 17, 18 suggesting that there are two types of CLL. The first, arises from relatively less differentiated (naïve Bcells) with unmutated V H genes, and has a poor prognosis. The second, evolves from more differentiated Blymphocytes with somatically mutated V H genes with a better prognosis than the unmutated phenotype.
Although, CLL B-cells have been assumed to be frozen in an immature stage 19 in vitro studies have suggested that these cells are not stationary at this stage of differentiation, since appropriate stimulation can
give rise to terminal differentiation 20, 21 and to CSR. 22, 23 In a recent work we have shown, that in contrast to normal circulating B-cells, AID transcripts are expressed constitutively in some CLL patients undergoing active CSR, but interestingly this expression occurs predominately in unmutated CLL B-cells. 24 Inhibitor of Differentiation (Id) proteins family plays a regulatory roles in the coordination of proliferation and differentiation, through sequestration of helix-loop-helix transcription factors and inhibition the DNA binding functions of different transcription factors like Pax-5 and Ets proteins. 25 In consequence, Id proteins appear to be involved in the process to CSR, particularly interacting with Pax-5 gene. 26 
Recent work from
Gonda et al, demonstrated that the balance between Pax-5 and Id-2 activities is key to the regulation of AID expression. 27 In addition, it has been reported that expression of Pax-5 28 and AID 29 genes are regulated by the transcriptional repressor Blimp-1 (B-cell lymphocyte-induced maturation protein-1), encoded by prdm-1 gene. 28 To gain insight into the molecular mechanisms underlying AID expression and CSR, we analyzed the expression level of Pax-5, Id-2, prdm-1 and AID genes in normal human B-cells and CLL B-cells upon CD40 ligand stimulation, which induces expression of AID.
Our results show that AID expression in CLL B-cells is subtly regulated by the differential expression of BSAP isoforms. The presence of AID protein is associated with expression of only the complete form of the Pax-5 gene (Pax-5a), whereas not expression of AID is associated with a reduction of Pax-5a mRNA and the appearance of a second spliced form with a complete deletion of exon 8 (Pax-5/∆-Ex8). Since the deleted form lacks an important fragment of the auto-regulatory activation domain while conserve the inhibitory region, we determined whether the appearance of this isoform was linked to control
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From of Pax-5a and AID expression. In this work, expression of the Pax-5/∆-Ex8 protein isoform and its capacity to bind to the AID gene promoter was assessed whereas expression of Pax-5a, Pax-5/∆-Ex8, Id-2 and prdm-1 transcripts was analyzed. Our results suggest that a subtle auto-regulation of Pax-5 gene products affects the expression of AID protein and is able to drive at least in CLL B-cells the process of CSR.
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MATERIALS AND METHODS

Healthy and CLL samples.
After informed consent, peripheral blood was obtained from 54 patients with typical diagnosis of B-CLL and 6 normal control donors. The CLL studied patients consisted of 32 males and 22 females, with a median age of 66 (range 43-90 years). Twenty-eight were in stage A, 15 in stage B and 11 in Stage C. Twenty-seven expressed unmutated V H genes whereas 27 expressed mutated genes ( Table 2) 
Phenotypic and functional studies of B-cells.
Peripheral blood mononuclear cells, (PBMC) were isolated by centrifugation on Ficoll-Hypaque.
Phenotypic analysis of CLL B-cells was performed with anti-CD19 phycoerythrin (PE), anti-CD5 fluorescein-isothiocyanate (FITC), and CSR process was evaluated by anti-human µ, δ, γ and α chains F(ab') 2 conjugated with FITC. All antibodies were from Dako (S.A, Paris, France). Data were acquired and analysis performed using an EPICS XL flow cytometer (Beckman/Coulter, Roissy, France). For CD40L+IL4 stimulation, B-cells were purified through negative depletion by using also a RosetteSep TM antibody cocktail (CD2, CD3, CD16, CD36, CD56) directly on peripheral blood as described by the supplier (StemCell Technologies INC, Vancouver, Canada). B-cell purity was shown to be >99% by flow cytometry. 
Analysis of RNA transcripts by RT-PCR
RNA was isolated from 5.10 6 B-cells and cDNA synthesis was performed as described. 24 cDNA of healthy and CLL B-cells was used for amplification of AID, Pax-5, Id-2, prdm-1 and isotype switch transcripts by polymerase chain reaction. The PCR protocol and the primers used for AID were performed as previously described. 24 Amplification of Ig family using 5'-V H leader specific primers together with a consensus J H primer in 3' was carried out, as previously described. 30 The primers used for amplification of Pax-5 are depicted in 
Quantitative Real Time PCR (QRT-PCR)
The QRT-PCR assay was performed using SYBR Green I method on the Light Cycler System (Roche increased whereas expression of Pax-5/∆-Ex8 and Id-2 was significantly reduced and AID transcripts were detected ( Fig. 4A-B) . In addition, not switch transcripts are observed in non-stimulated CLL B-cells/AID (-) , but after stimulation this patient become able to undergo CSR (Fig. 4C) as it is confirmed by sequence of
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From VDJ-µ, δ and γ fragments (data not shown), and flow cytometry analysis in figure 3C . The clonal origin of these switch variants was substantiated following cell-sorting experiments for patients 1 and 2, (table 3) (Fig. 5a ). In contrast, a significant diminution (p<0,01) was found after activation of CLL B-cells/AID (-) (Fig. 5b) , suggesting that expression of prdm-1 gene is inversely correlated to BSAP and AID protein expression, two essential molecules in the CSR process.
Complete form of Pax-5 and spliced Pax-5/∆-Ex8 isoforms bind the AID promoter.
To determine if BSAP in its complete form or in its spliced variant deleted in exon 8 are able to bind the promoter of AID gene we have designed oligoprobes bearing the Pa3 and performed EMSA assays.
Nuclear extracts prepared from CLL B-cells/AID (+) with restricted expression of Pax-5a (patient 01) and CLL B-cells/AID (-) with expression of both, Pax-5a and Pax-5/∆-Ex8 (patient 28), were tested for binding to this oligoprobes. After 3 hr exposure two complexes were detected in CLL B-cells/AID (+) and three complexes in CLL B-cells/AID (-) (Fig. 6a) . For control purposes, competitive experiments using different concentrations of the homologous unlabelled fragment (Pa3) were performed. Two complexes (a and b in figure 6 ) from CLL B-cells/AID (-) and one (band a in figure 6 ) from CLL B-cells/AID (+) were inhibited following incubation with 100 ng of unlabelled fragment. In addition, 25 ng of labeled DNA Pa3 oligoprobes
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From were incubated with increasing amounts of nuclear extracts and a protein-dependent concentration effect was visualized, (data not shown). In order to confirm the specificity of these interactions we carried out western blot analysis of these DNA-proteins complexes with C-terminal anti-BSAP antibody. The results show that one of the two complexes in a CLL B-cells/AID (+) patient 01 is specifically recognize by anti-BSAP antibody as shown in figure 6b, whereas two complexes are identified in a CLL B-cells/AID (-) (patient 28). These results suggest that spliced form of BSAP (Pax-5/∆-Ex8) described here is also able to bind DNA Pa3 region of promoter AID gene. and CSR process. Since the discovery of AID, the knowledge of CSR has considerably advanced. In the present is possible to envisage a mechanistic model of this process linking AID-mediated DNA deamination on the unique primary structure of S regions and the requirements for germline transcription. 37 However, several aspects of CSR both upstream and downstream of AID remain unsolved.
In this work we attempted to gain insight into the multifaceted mechanism of CSR by studying BSAP and Id-2 protein since both, are key molecules in the regulation of AID gene. 27 Alternative splicing of transcription factors increases the regulatory capacities for gene expression, and this mechanism is commonly used within the several families of transcription factors. The full-length Pax-5a transcripts has been identified and characterized in B-lymphocytes, mouse and human cell lines. 14, 38 In addition to Pax-5a, three isoforms of BSAP (Pax-5b, Pax-5d, and Pax-5e) were described in mouse by Zwollo et al. 32 Pax-5b aa located in exons 9-10 has been identified like the inhibitory domain. The first and last of these exons (8 and 10) code exclusively for transactivating or inhibitory aa residues, respectively, while the second exon (9) contributes to both protein domains. 13 ( Figure 1 ). In mouse B-cells it has been demonstrated that the spliced form Pax-5d has the ability to act as a transcriptional suppressor and in addition can repress the activity of Pax-5a. 42 Pax-5/∆-Ex8 described in human B-cells include a complete deletion of exon 8 and lacks more than 50 % of the sequence described by Dorfler et al like a "minimal transactivation domain" of BSAP. 13 In a recent work it has been proposed that Pax-5a up-regulates AID gene expression, through binding to its promoter region. 27 Since the isoform Pax-5/∆-Ex8 conserve a paired domain for DNA binding function we performed EMSA assays to define the putative function of this isoform in the control of AID expression. For personal use only. on October 3, 2017. by guest www.bloodjournal.org From 
